Business

Acerus has announced the completion of its acquisition of Serenity Pharmaceuticals LLC and the acquisition of its global rights to Noctiva ™ in the Canadian Business Journal.

Toronto, March 7, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (“society” Also “Asselus(TSX: ASP; OTCQB: ASPCF) today announced the completion of the previously announced acquisition of Serenity Pharmaceuticals LLC (“Serenity”), which includes global rights to the Noctiva ™ brand. Based in Miami, Florida, Serenity is a specialized pharmaceutical company focused on developing treatments for diseases associated with dysuria, formerly from the US Food and Drug Administration (FDA) Noctiva ™ (desmopressin acetate) nasal spray. Was approved by. Details of this transaction can be found in our filings in the United States and Canada.

Acerus will host an investor call to discuss the acquisition of Serenity on March 9, 2022, at 8:30 EST. To access the call live, dial 416-406-0743 or 1-800-952-5114 and use access code 4028136 #. Listeners are advised to dial 10 minutes before starting a call to avoid delays. For conference call replays, dial 905-694-9451 or 1-800-408-3053 using access code: 3378123 # until 11:59 pm Eastern Standard Time on Wednesday, March 16, 2022. available.

Edward Gudaitis, President and Chief Executive Officer of Acerus Pharmaceuticals, said: “The integrated enterprise will provide a wide range of products to the North American urology and men’s health markets and leverage its expanding footprint to strengthen its outlook for the coming years.”

Presentations and FAQ documents that Acerus covers by phone to investors can be found on the Acerus Investor Page website, at the links below, and at SEDAR.

Presentation: http: //www.aceruspharma.com/files/doc_downloads/2022/Acerus-Serenity-Combo_Public-deck_final_03072022.pdf

FAQ: http: //www.aceruspharma.com/files/doc_downloads/2022/ASP-SER-Acqusition-Public-FAQs_final_03072022.pdf

About Acerus

Acerus Pharmaceuticals Corporation is a specialized pharmaceutical company focused on the commercialization and development of innovative prescription drug products that improve the patient experience, with a primary focus on the field of male health. We commercialize our products through our sales force in the United States and Canada, as well as our global network of authorized distributors in other regions.

Shares of Acerus are traded on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, please visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

About Serenity

Founded in 2006 and located in Miami, Florida, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that affect the health and well-being of millions of people. Serenity Pharmaceuticals is committed to developing patented medicines with unique delivery mechanisms and formulations to provide safe and effective treatments for dysuria.

Notice of future prospects

Except for statements of historical facts relating to Acerus or Serenity, certain statements contained in this press release provide forward-looking information, forward-looking financial information, or financial outlook (collectively) in the sense of applicable securities law. And make up “Information about the future outlook”). Information about future prospects may be included in this document and other public filings of Acerus. Information on future prospects relates to statements regarding the outlook for Acerus and the merged company, statements regarding expected events or outcomes, statements regarding the expectations of Acerus management, including the completion of the acquisition, and statements regarding the merged company, including expected net income. I am. In some cases, the merged company may “may”, “do”, “done”, “should”, “expect”, “plan”, “predict”, “expect”, It can be identified by terms such as “believe”. , “Intention,” “estimate,” “project,” “predict,” “potential,” “continue,” or other similar expression for matters that are not historical facts.

The forward-looking information in this press release is based on certain key expectations and assumptions by Acerus, including expectations and assumptions regarding the completion of the acquisition. Acerus believes that the expectations and assumptions underlying such forward-looking information are reasonable, but Acerus cannot provide any assurance that they are correct and therefore regarding future prospects. You should not place excessive trust in the information. Information about future prospects is subject to various risks and uncertainties, and actual results and experience may differ materially from the expected results or expectations contained in this press release. Key risks and uncertainties include, but are not limited to, acquisitions that do not complete as expected. Delay or failure to resume production of Noctiva. Not being able to raise enough funds could lead to the proper launch of Noctiva and the failure to meet Acerus’ expected revenue targets. Unable to maintain continuous production of Natesto or Noctiva due to quality issues, supply chain disruptions, or events at contract manufacturers that produce both products. Failure to achieve or sustain appropriate and competitive commercial and government reimbursement for either Natesto or Noctiva to major payers in the United States or other major markets. The merged company failed to achieve the expected market share of product acceptance in the market. Unable to secure key personnel or replace departures in a timely manner. The merged companies merged and failed to achieve the expected synergies. Profitability and feasibility of an integrated entity. Ability of Acerus and the merged company to continue as a going concern. Acerus’s expected ability to raise the capital needed to pay the purchase price and fund the operation of the merged company. Continued commercialization and sale of products. Market acceptance of the company’s products. General admission risk and intellectual property risk. Risks associated with company marketing and distribution, and dependence on third-party manufacturers and suppliers. Risks associated with product safety or effectiveness concerns that may lead to proceedings, regulatory measures, product recalls or withdrawals. Government and regulatory requirements and actions by government and regulatory agencies, including government policies, taxes, prescription drug pricing and rebates, and other changes in laws or regulations and their interpretations. Developments on the COVID-19 pandemic, including the duration, severity, scope, and potential impact on operations and supply chains of the pandemic. The fact that the merged company will continue to have controlling shareholders. Other risk factors detailed from time to time in the Acerus report filed with Canadian securities regulators. For more complete information on these risks and uncertainties, please refer to the March 10, 2021 Annual Information Form available at www.sedar.com. We believe that the forward-looking information contained in this press release is based on our current estimates, expectations and forecasts and is reasonable as of the current date. Do not overly rely on information about future prospects or rely on this information at other dates. We may choose, but we are not obligated to update this information at any particular time as new information, future events, or other consequences, except as required by applicable securities law. We shall not be obliged to do so.

Company contact information
ir@aceruspharma.com

Investor Publicist
Chris Witty
Acerus Investor Relations
(646) 438-9385
cwitty@darrowir.com


CBJ News Maker

Acerus has announced the completion of its acquisition of Serenity Pharmaceuticals LLC and the acquisition of its global rights to Noctiva ™ in the Canadian Business Journal.

Source link Acerus has announced the completion of its acquisition of Serenity Pharmaceuticals LLC and the acquisition of its global rights to Noctiva ™ in the Canadian Business Journal.

Related Articles

Back to top button